NCT03792958 is a Phase 1 clinical trial of CM082 in Advanced Malignant Solid Tumors, sponsored by AnewPharma.

Who is sponsoring NCT03792958?

NCT03792958 is sponsored by AnewPharma.

What drugs are being tested in NCT03792958?

Interventions in NCT03792958: CM082.

What condition does NCT03792958 study?

NCT03792958 studies Advanced Malignant Solid Tumors.

Is NCT03792958 still recruiting?

NCT03792958 is currently status unknown. Last updated 10 November 2022.

Last reviewed 2022-11-10 · How we verify

NCT03792958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of CM082 Tablets in the Treatment of Advanced Malignant Solid Tumors: Safety, Tolerance and Pharmacokinetics

Status unknown Phase 1 Last updated 10 November 2022

What this trial tests

Phase 1 trial testing CM082 in Advanced Malignant Solid Tumors in 19 participants. Status unknown.

Timeline

26 February 2019

Primary endpoint
1 June 2023

1 June 2023

Quick facts

Lead sponsor	AnewPharma
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	26 February 2019
Primary completion	1 June 2023
Estimated completion	1 June 2023
Sites	1 location across China

Drugs / interventions tested

CM082 — full drug profile →

Conditions studied

Advanced Malignant Solid Tumors — all drugs for Advanced Malignant Solid Tumors →

Sponsor

AnewPharma — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum tolerable dose (MTD) or dose to absorb saturation
Time frame: From the first dose to the 28th day of administration
Dose-Limiting Toxicity
Time frame: From the first dose to the 28th day of administration
Characteristics of dose-limiting toxicity (DLT), evaluation criteria: National Cancer Institute (NCI) CTC classification (version 4.03)
Pharmacokinetic parameters
Time frame: From the first dose to the 28th day of administration
Peak concentration
Pharmacokinetic parameters
Time frame: From the first dose to the 28th day of administration
Area under the time curve of blood concentration from 0 h to the last time of blood collection
Pharmacokinetic parameters
Time frame: From the first dose to the 28th day of administration
0 to Infinite Area under Blood Drug Concentration Curve
Pharmacokinetic parameters
Time frame: From the first dose to the 28th day of administration
Peak time

Sponsor's own description

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tumour-associated macrophages: versatile players in the tumour microenvironment.
Ji ZZ, Chan MK, Chan AS, Leung KT, et al · · 2023 · cited 18× · PMID 37965573 · DOI 10.3389/fcell.2023.1261749

Verify or expand the search:

Other trials of CM082

Trials testing the same drug.

NCT04222842 — CM082 in Patients With Myopic Choroidal Neovascularization (CNV) · Phase 1 · suspended
NCT03710863 — Safety and Tolerability of Oral CM082 in Patients With wAMD · Phase 2 · unknown

Other recruiting trials for Advanced Malignant Solid Tumors

Currently open trials in the same condition.

NCT07292402 — JSKN022 in Subjects With Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT06717750 — A Study of CSCJC3456 in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
NCT06728189 — A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT06499350 — A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06571422 — Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors · Phase 1 · recruiting

Other AnewPharma trials

Trials by the same sponsor.

NCT04434326 — The Absorption, Metabolism and Excretion of [14C]CM082 in Human · Phase 1 · completed
NCT04328506 — Bioequivalency Study of CM082 Tablet in Healthy Volunteers · Phase 1 · completed
NCT04126668 — A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers · Phase 1 · completed
NCT04222842 — CM082 in Patients With Myopic Choroidal Neovascularization (CNV) · Phase 1 · suspended
NCT03904719 — CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03792958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AnewPharma
Last refreshed: 10 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03792958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing